Characteristics of the cohort with KSHV-associated diseases stratified according to clinical classification into distinct KAD categories
| Characteristic . | KS . | MCD . | MCD + PEL . | KICS + KS . | PEL . |
|---|---|---|---|---|---|
| (n = 10) . | (n = 11) . | (n = 5) . | (n = 11) . | (n = 5) . | |
| Age, y | 29 (26.3-45.5) | 43 (40.5-44.8) | 55 (55-55) | 37 (30.5-49.5) | 39 (38-52) |
| Male, n | 10 | 10 | 5 | 10 | 5 |
| Race, n | |||||
| Hispanic | 0 | 1 | 0 | 3 | 1 |
| African/African-American | 5 | 4 | 2 | 5 | 1 |
| White | 4 | 5 | 3 | 2 | 2 |
| Other | 1 | 1 | 0 | 1 | 1 |
| BMI (kg/m2) | 22.6 (20.9-27.2) | 24.3 (22.6-27.1) | 23.2 (22.8-23.3) | 23.8 (20.5-27.4) | 24.6 (24.5-26.5) |
| Time from ART initiation to sample collection (wk) | 17.9 (3.8-32.6) | 125 (32-282) | 174 (59-260) | 6.9 (2.2-114) | 265 (22-650) |
| ECOG score | 0 (0-1) | 1 (1-3) | 2 (1-3) | 2 (1-2) | 2 (1-3) |
| KS stage, n | |||||
| Stage T0 | 2 | 1 | 0 | 2 | 0 |
| Stage T1 | 8 | 1 | 5 | 9 | 2 |
| CD4 T cells per μL | 208 (114-305) | 263 (190-531) | 318 (250-363) | 48 (33-111) | 401 (170-594) |
| CD19 B cells per μL | 113 (67-195) | 233 (104-377) | 174 (141-259) | 32 (11-62) | 197 (180-231) |
| Hemoglobin (g/dL) | 11.2 (9.9-14.0) | 10.3 (9.0-11.5) | 8.0 (7.9-9.1) | 8.6 (7.9-9.8) | 11.2 (9.6-12.2) |
| Platelets (×103/μL/μL) | 246 (197-284) | 171 (59-265) | 276 (253-347) | 212 (118-292) | 361 (176-371) |
| HIV-VL (log10 IU/mL) | 1.1 (0.7-2.1) | 1.0 (1.0-1.8) | 2.7 (1.7-2.8) | 2.9 (2.2-4.6) | 0.7 (0.7-3.0) |
| Ferritin (ng/mL) | 312 (117-554) | 833 (582-2920) | 1209 (366-2167) | 1219 (590-1678) | 565 (449-1143) |
| CRP (mg/L) | 9.15 (4.8-13.0) | 33.9 (17.0-109.4) | 51.0 (48.8-65.7) | 52.4 (14.6-83.2) | 61.4 (33.5-62.6) |
| KSHV-VL (log10 copies per million cells) | 0.0 (0.0-1.9) | 4.0 (3.4-5.0) | 3.6 (3.2-4.2) | 3.8 (3.4-4.6) | 4.4 (4.2-4.6) |
| Concurrent KS, n | N/A | 2 | 5 | 11 | 1 |
| Prior therapy, n | 4 | 6 | 3 | 4 | 1 |
| Chemotherapy (<1 mo) | 3 | 1 | 0 | 2 | 0 |
| Chemotherapy (<6 mo) | 1 | 1 | 3 | 2 | 1 |
| Corticosteroids (<6 mo) | 0 | 3 | 0 | 0 | 0 |
| Rituximab (<1 y) | 0 | 2 | 0 | 1 | 0 |
| Characteristic . | KS . | MCD . | MCD + PEL . | KICS + KS . | PEL . |
|---|---|---|---|---|---|
| (n = 10) . | (n = 11) . | (n = 5) . | (n = 11) . | (n = 5) . | |
| Age, y | 29 (26.3-45.5) | 43 (40.5-44.8) | 55 (55-55) | 37 (30.5-49.5) | 39 (38-52) |
| Male, n | 10 | 10 | 5 | 10 | 5 |
| Race, n | |||||
| Hispanic | 0 | 1 | 0 | 3 | 1 |
| African/African-American | 5 | 4 | 2 | 5 | 1 |
| White | 4 | 5 | 3 | 2 | 2 |
| Other | 1 | 1 | 0 | 1 | 1 |
| BMI (kg/m2) | 22.6 (20.9-27.2) | 24.3 (22.6-27.1) | 23.2 (22.8-23.3) | 23.8 (20.5-27.4) | 24.6 (24.5-26.5) |
| Time from ART initiation to sample collection (wk) | 17.9 (3.8-32.6) | 125 (32-282) | 174 (59-260) | 6.9 (2.2-114) | 265 (22-650) |
| ECOG score | 0 (0-1) | 1 (1-3) | 2 (1-3) | 2 (1-2) | 2 (1-3) |
| KS stage, n | |||||
| Stage T0 | 2 | 1 | 0 | 2 | 0 |
| Stage T1 | 8 | 1 | 5 | 9 | 2 |
| CD4 T cells per μL | 208 (114-305) | 263 (190-531) | 318 (250-363) | 48 (33-111) | 401 (170-594) |
| CD19 B cells per μL | 113 (67-195) | 233 (104-377) | 174 (141-259) | 32 (11-62) | 197 (180-231) |
| Hemoglobin (g/dL) | 11.2 (9.9-14.0) | 10.3 (9.0-11.5) | 8.0 (7.9-9.1) | 8.6 (7.9-9.8) | 11.2 (9.6-12.2) |
| Platelets (×103/μL/μL) | 246 (197-284) | 171 (59-265) | 276 (253-347) | 212 (118-292) | 361 (176-371) |
| HIV-VL (log10 IU/mL) | 1.1 (0.7-2.1) | 1.0 (1.0-1.8) | 2.7 (1.7-2.8) | 2.9 (2.2-4.6) | 0.7 (0.7-3.0) |
| Ferritin (ng/mL) | 312 (117-554) | 833 (582-2920) | 1209 (366-2167) | 1219 (590-1678) | 565 (449-1143) |
| CRP (mg/L) | 9.15 (4.8-13.0) | 33.9 (17.0-109.4) | 51.0 (48.8-65.7) | 52.4 (14.6-83.2) | 61.4 (33.5-62.6) |
| KSHV-VL (log10 copies per million cells) | 0.0 (0.0-1.9) | 4.0 (3.4-5.0) | 3.6 (3.2-4.2) | 3.8 (3.4-4.6) | 4.4 (4.2-4.6) |
| Concurrent KS, n | N/A | 2 | 5 | 11 | 1 |
| Prior therapy, n | 4 | 6 | 3 | 4 | 1 |
| Chemotherapy (<1 mo) | 3 | 1 | 0 | 2 | 0 |
| Chemotherapy (<6 mo) | 1 | 1 | 3 | 2 | 1 |
| Corticosteroids (<6 mo) | 0 | 3 | 0 | 0 | 0 |
| Rituximab (<1 y) | 0 | 2 | 0 | 1 | 0 |
Data represent medians with interquartile range for continuous variables and frequencies for categorical variables. KSHV-VL represents copies per million PBMCs. Prior therapy refers to immune modulation therapies or chemotherapy in the year before sample collection: doxorubicin, pomalidomide, cyclophosphamide, corticosteroids, and rituximab.
ECOG, Eastern Cooperative Oncology Group.